Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|June 4, 2017
Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trialRuth E Cooper, Emma Williams, Seth Seegobin, et al.
Personality and Mental Health|August 29, 2015
Validation of the standardised assessment of personality--abbreviated scale in a general population sampleMarcella Lei-Yee Fok, Seth Seegobin, Souci Frissa, et al.
The Oncologist|April 1, 2014
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancerHyman Muss, Javier Cortes, Linda T Vahdat, et al.
Infectious Diseases and Therapy|May 4, 2024
Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER TrialsMyron J Levin, Andrew Ustianowski, Stephane De Wit, et al.
JAMA Dermatology|August 18, 2021
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical TrialSophie Glatt, Gregor B E Jemec, Seth Forman, et al.
Clinical & Translational Immunology|June 14, 2024
Serum AZD7442 (tixagevimab-cilgavimab) concentrations and <i>in vitro</i>IC<sub>50</sub> values predict SARS-CoV-2 neutralising antibody titresLindsay E Clegg, Oleg Stepanov, Sam Matthews, et al.
Infectious Diseases and Therapy|February 25, 2024
Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE TrialF D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
The Journal of Infectious Diseases|January 23, 2023
Safety, Tolerability and Pharmacokinetics of Half-Life Extended Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Monoclonal Antibodies AZD7442 (Tixagevimab-Cilgavimab) in Healthy AdultsPablo Forte-Soto, Muna Albayaty, Dennis Brooks, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 9, 2016
Macrophage migration inhibitory factor protects from nonmelanoma epidermal tumors by regulating the number of antigen-presenting cells in skinTania Brocks, Oleg Fedorchenko, Nicola Schliermann, et al.
Infectious Diseases and Therapy|September 26, 2023
Outpatient Treatment with AZD7442 (Tixagevimab/Cilgavimab) Prevented COVID-19 Hospitalizations over 6 Months and Reduced Symptom Progression in the TACKLE Randomized TrialF D Richard Hobbs, Hugh Montgomery, Francisco Padilla, et al.
Pageof 2